Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | TACR2 | P21452 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25286068 | 0.88 | MEN1 (0.57) | GRM5KDRMEN1KMT2ATACR2 | |
| SCHEMBL25233673 | 0.88 | GRM5 (0.56) | GRM5KDRMEN1KMT2ATACR2 | |
| SCHEMBL25232354 | 0.87 | GRM5 (0.54) | GRM5KDRTACR2TACR1 | |
| SCHEMBL25846457 | 0.86 | GRM5 (0.53) | GRM5KDRTACR2TACR1 | |
| SCHEMBL25274902 | 0.85 | TRPV1 (0.58) | GRM5TACR2TACR1 | |
| SCHEMBL30563504 | 0.85 | NPC1 (0.54) | GRM5MEN1KMT2ATACR2TACR1 | |
| SCHEMBL25246000 | 0.85 | NPC1 (0.54) | GRM5MEN1KMT2ATACR2TACR1 | |
| SCHEMBL25281475 | 0.83 | TACR2 (0.54) | GRM5KDRTACR2TACR1 | |
| SCHEMBL25233978 | 0.83 | GRM5 (0.55) | GRM5KDRMEN1KMT2ATACR2 | |
| SCHEMBL25237004 | 0.83 | NPC1 (0.57) | GRM5KDRMEN1KMT2ATACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009447-A1 | Substituted Benzoic Acid Amides and Use thereof for the Inhibition of Angiogenesis | SCHERING AG (DE) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009447-A1 | Substituted Benzoic Acid Amides and Use thereof for the Inhibition of Angiogenesis | VEGFA, EGLN2, HIF1AN | GRM5 2930/4885KDR 8/4885MEN1 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.